Lab Information

Marina Klein (MD/MSc)

Senior Scientist
Centre for Outcomes Research and Evaluation
Department of Medicine (McGill)

Research Profile

 Fundamental: 0%
 Clinical: 20%
 Epidemiology: 80%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.
 http://www.cocostudy.ca/

Keywords

HIV • Hepatitis C • clinical trials • epidemiology • antiretrovirals • prospective cohort

Research Interests

My research focuses on the treatment of patients with HIV and chronic hepatitis. As a prominent researcher in clinical and epidemiologic aspects of HIV and Hepatitis C co-infection, I lead one the largest multicenter cohorts focused on HIV/HCV co-infection in the world, recruiting more than one thousand HIV/HCV co-infected patients across Canada. The primary objectives of the CIHR funded cohort are to study the interactions between these two chronic viruses and their natural history in the era of combination antiretroviral therapy (cART) and to evaluate therapeutic strategies aimed at improving health outcomes in co-infected persons. We are also focused on understanding the roles of co-morbidities in the natural history of HIV/HCV co-infection. In addition, I am involved in a number of observational epidemiologic research collaborations (NA-ACCORD and CANOC) that focus on understanding long term clinical and treatment outcomes in HIV infection. My other research interests include antiretroviral pharmacoepidemiology and HIV infection in women.


Team Members

Name Position

Latest Publications

  1. Kaufman, E., Williamson, T., Mayrand, M.-H., Burchell, A. N., Klein, M., Charest, L., Rodrigues-Coutlée, S., Coutlée, F., de Pokomandy, A. & EVVA study group (2022). Identifying risk factors for prevalent anal human papillomavirus type 16 infection in women living with HIV. PloS one, vol. 17, p. e0268521.
  2. Rodriguez Duque, D., Stephens, D. A., Moodie, E. E. M. & Klein, M. B. (2022). Semiparametric Bayesian inference for optimal dynamic treatment regimes via dynamic marginal structural models. Biostatistics (Oxford, England).
  3. Lee, J. S., Humes, E., Hogan, B. C., Justice, A. C., Klein, M., Gebo, K., John Gill, M., Silverberg, M. J., Rebeiro, P., Horberg, M., Karris, M., Rabkin, C., Moore, R. D., Althoff, K. N. & North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (2022). Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. The lancet. HIV, vol. 9 Suppl 1, p. S2.
  4. Lanièce Delaunay, C., Maheu-Giroux, M., Marathe, G., Saeed, S., Martel-Laferrière, V., Cooper, C. L., Walmsley, S., Cox, J., Wong, A., Klein, M. B. & Canadian Coinfection Cohort investigators (2022). Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. The International journal on drug policy, vol. 103, p. 103627.
  5. Kim, H. N., Nance, R. M., Lo Re, V., Silverberg, M. J., Franco, R., Sterling, T. R., Cachay, E. R., Horberg, M. A., Althoff, K. N., Justice, A. C., Moore, R. D., Klein, M., Crane, H. M., Delaney, J. A. & Kitahata, M. M. (2022). Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. Journal of acquired immune deficiency syndromes (1999), vol. 89, p. 396-404.
  6. Ali, K., Azher, T., Baqi, M., Binnie, A., Borgia, S., Carrier, F. M., Cavayas, Y. A., Chagnon, N., Cheng, M. P., Conly, J., Costiniuk, C., Daley, P., Daneman, N., Douglas, J., Downey, C., Duan, E., Duceppe, E., Durand, M., English, S., Farjou, G., Fera, E., Fontela, P., Fowler, R., Fralick, M., Geagea, A., Grant, J., Harrison, L. B., Havey, T., Hoang, H., Kelly, L. E., Keynan, Y., Khwaja, K., Klein, G., Klein, M., Kolan, C., Kronfli, N., Lamontagne, F., Lau, R., Fralick, M., Lee, T. C., Lee, N., Lim, R., Longo, S., Lostun, A., MacIntyre, E., Malhamé, I., Mangof, K., McGuinty, M., Mergler, S., Munan, M. P., Murthy, S., O'Neil, C., Ovakim, D., Papenburg, J., Parhar, K., Parvathy, S. N., Patel, C., Perez-Patrigeon, S., Pinto, R., Rajakumaran, S., Rishu, A., Roba-Oshin, M., Rushton, M., Saleem, M., Salvadori, M., Scherr, K., Schwartz, K., Semret, M., Silverman, M., Singh, A., Sligl, W., Smith, S., Somayaji, R., Tan, D. H. S., Tobin, S., Todd, M., Tran, T.-V., Tremblay, A., Tsang, J., Turgeon, A., Vakil, E., Weatherald, J., Yansouni, C., Zarychanski, R., Canadian Treatments for COVID-19 (CATCO) & Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group (2022). Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, vol. 194, p. E242-E251.
  7. Isnard, S., Fombuena, B., Ouyang, J., Royston, L., Lin, J., Bu, S., Sheehan, N., Lakatos, P. L., Bessissow, T., Chomont, N., Klein, M., Lebouché, B., Costiniuk, C. T., Routy, B., Marette, A., Routy, J.-P. & Camu Camu Study Group (2022). Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032). BMJ open, vol. 12, p. e053081.
  8. Klein, M. B. (2022). Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. The lancet. Gastroenterology & hepatology, vol. 7, p. 277-279.
  9. Engler, K., Vicente, S., Ma, Y., Hijal, T., Cox, J., Ahmed, S., Klein, M., Achiche, S., Pant Pai, N., de Pokomandy, A., Lacombe, K. & Lebouché, B. (2021). Implementation of an electronic patient-reported measure of barriers to antiretroviral therapy adherence with the Opal patient portal: Protocol for a mixed method type 3 hybrid pilot study at a large Montreal HIV clinic. PloS one, vol. 16, p. e0261006.
  10. Young, J., Lo Re, V., Kim, H. N., Sterling, T. R., Althoff, K. N., Gebo, K. A., Gill, M. J., Horberg, M. A., Mayor, A. M., Moore, R. D., Silverberg, M. J., Klein, M. B. & North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA (2022). Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. Pharmacoepidemiology and drug safety, vol. 31, p. 214-224.
More on PubMed 



See also

Card image
Joseph
Cox


See profile
Card image
Bertrand
Lebouché


See profile
Card image
Christos
Tsoukas


See profile
Card image
Nadine
Kronfli


See profile
Card image
Giada
Sebastiani


See profile
Card image
Alexandra
De Pokomandy


See profile